Related Experiment Video
Updated: Jul 4, 2026
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction
1Innovative Research Institute for Cell Therapy, Department of Internal Medicine, Seoul National University Hospital, 28 Yongun-Dong, Chongno-Gu, Seoul, 110-744, South Korea. hyosoo@snu.ac.kr
Insights
Granulocyte colony-stimulating factor (G-CSF) and erythropoietin show potential for treating myocardial infarction by improving heart function. However, clinical trials indicate that these cytokines alone are not effective, necessitating further research into combined therapies.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Regenerative Medicine
Background:
- Granulocyte colony-stimulating factor (G-CSF) and erythropoietin are cytokines with potential cardiovascular benefits.
- Initially explored for stem cell mobilization and cytoprotection, respectively, both exhibit direct cytoprotective and stem cell-mobilizing properties.
- The Jak-STAT pathway is a common mediator for the direct cytoprotective effects of these cytokines.
Purpose of the Study:
- To review the potential of G-CSF and erythropoietin in improving cardiac function and perfusion post-myocardial infarction.
- To investigate the underlying mechanisms, including angiomyogenesis and cardiomyocyte protection.
- To address the discrepancy between preclinical findings and clinical trial outcomes.
Main Methods:
- Review of preclinical studies demonstrating the efficacy of G-CSF and erythropoietin in myocardial infarction models.
- Analysis of results from recent clinical trials involving G-CSF or erythropoietin therapy in myocardial infarction patients.
- Exploration of the Jak-STAT pathway's role in mediating cytokine effects.
Main Results:
- Preclinical studies showed G-CSF and erythropoietin improved cardiac function and perfusion through angiomyogenesis and cardiomyocyte protection.
- Recent clinical trials did not support the beneficial effects of G-CSF or erythropoietin monotherapy in myocardial infarction.
- Both cytokines possess direct cytoprotective effects and stem cell-mobilizing abilities, often mediated via the Jak-STAT pathway.
Conclusions:
- While preclinical data suggest therapeutic benefits, G-CSF and erythropoietin alone have not proven effective in clinical trials for myocardial infarction.
- Further research is essential to fully understand the mechanisms of action of these cytokines.
- Novel therapeutic strategies, potentially involving combined cytokine administration, are required to enhance treatment efficacy for myocardial infarction.
Abstract:
Granulocyte colony-stimulating factor (G-CSF) and erythropoietin are two cytokines that have been demonstrated to improve cardiac function and perfusion in myocardial infarction. G-CSF was initially evaluated as a stem cell mobilizer and erythropoietin as a cytoprotective agent. However, both cytokines have direct cytoprotective effects and stem cell-mobilizing ability. Direct cytoprotective effects of both cytokines are commonly mediated by the Jak-STAT pathway. In preclinical study, G-CSF and erythropoietin improved cardiac function and perfusion by angiomyogenesis and protection of cardiomyocytes in myocardial infarction. However, results from recent clinical trials did not support beneficial effects of cytokine therapy with G-CSF or erythropoietin alone in patients with myocardial infarction. Further studies are required to elucidate the mechanism of action and to improve therapeutic efficacy by employing novel strategies, such as combined cytokines.
